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Abstract
　We reported a patient with multiple myeloma who 
developed myelomatous pleural effusion （MPE）. 
This patient had nine courses of chemotherapy, and 
pleural effusion developed after the fourth course. 
Although administration of several chemotherapeutic 
agents and intrapleural administration of OK432 
were performed, the patient died 4 months after 
the development of MPE. We analyzed the previous 
reports to clarify the characteristics of patients who 
developed MPE.
Introduction 
 Multiple myeloma（MM）is a malignant proliferation 
of plasma cells that usually invades the bone 
marrow but can involve many other organs as well
［1］. Extraosseous involvement of myeloma is 
usually observed in the reticuloendothelial system. 
Direct pulmonary/pleural involvement or myelomatous 
pleural effusion（MPE）is rare among the thoracic 
manifestations of the disease, with an incidence 
rate of less than 1％［2］. We reported a case in 
which MPE developed after the fourth course of 
chemotherapy. Although several courses of 
chemotherapy and intrapleural infusion of OK432 
（Pcibanil）were administered, the patient died 4 
months after the development of MPE. We 
reviewed the previous reports and analyzed 60 
cases to clarify the characteristics of patients who 
developed MPE.
Case Report
　The patient, a 66-year-old female, had developed 
multiple myeloma. On admission, her red blood cell 
count was 2440×10９/l, hemoglobin level was 7.8 
g/dl, leukocyte count was 3.0× 10９/l（stab and 
segmented neutrophiles：39％, metamyelocytes：2％, 
eosinophils：2％, monocytes：8％, lymphocytes：49％）, 
platelet count was 70.0×10９/l, lactate dehydrogenase 
（LDH）was 400IU/l, serum albumin was 4.0g/dl, 
and C-reactive protein was 0.1mg/dl （normal range 
is below 0.3mg/dl）. Her immunoglobulin G（IgG） 
count was 5622mg/dl（normal range is from 880 to 
1840）, and a monoclonal protein of the IgG-k type 
was detected. The patient’s serum β2-microglobulin 
level was 4.11mg/l （normal range is 0.8-1.9mg/l）. 
A bone marrow aspiration demonstrated normocellular 
marrow with 59.2％ plasma cells. Although the 
patient was treated with 2 courses of ranimustine 
（MCNU：70mg/m2 for 1 day）, vindesine sulfate 
（3mg/m2 for 1 day）, melphalan（8mg/m2 for 4 days）, 
and prednisolone（60mg/day for 5 days）, the effect 
of this chemotherapy was transient, resulting in 
increased plasma cells in the bone marrow up to 
70.6％ thereafter. The chemotherapy was changed 
to administration of 2 courses of cyclophosphamide 
（500mg/day for 1 day）and methyl-prednisolone 
（mPSL：500mg/day for 5 days）and a continuous 
infusion of vincristine sulfate （0.4mg/day for 4 
days） and doxorubicin hydrochloride （9mg/day for 
4 days）. After the first course of this chemotherapy, 
IgG level decreased to 1526mg/dl and plasma cells 
in bone marrow decreased to 12.0％. Thalidomide 
was subsequently administered to the patient. Pleural 
effusion was observed 2 days after the administration 
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of thalidomide （Figure 1）, and myeloma cells were 
found in the pleural effusion（Figure 2）. Two courses 
of a CHOP regimen （cyclophosphamide：750mg/m2, 
vincristine：1.4mg/m2, doxorubicin hydrochloride：
50mg/m2 for 1 day, and prednisolone：60mg/day 
for 5 days） were therefore administered. Although 
the myelomatous effusion and plasma cells in bone 
marrow decreased after the first course of CHOP, 
MPE and plasma cells in the bone marrow increased 
after the second course. The MPE was controlled 
by intrapleural administration of OK432. This was 
followed by administration of cyclophosphamide 
（250mg/day for 4 days）, etoposide （50mg/day for 
7 days）, mPSL （500mg/day for 5 days）, and thalidomide 
（100mg/day for 7 days）. However, the disease 
progressed and the patient died of respiratory 
failure due to lymphangitis brought on by the 
myeloma cells after 2 courses of cyclophosphamide 
treatment. 
Patients and methods
Patients
　We searched MEDLINE for reports on MPE 
patients. Forty-eight reports were found in the 
listed literature. Among these reports, we selected 
those in which the development of MPE was clearly 
mentioned. Sixty-eight such patients were reviewed 
in this analysis. 
Statistical Analysis
　Statistical tests were performed with Statview 
（Brain Power, Calabasas, CA, USA） software, 
and the data were expressed as mean ± SD or 
median（range）. Statistically significant differences 
in the analyzed data were determined by the 
Student’s-t test. For all of these tests, a P value of 
less than 0.05 was considered a statistically 
significant difference.
Results 
Characteristics of MPE patients
　The characteristics of the analyzed patients are 
shown in Table 1. The age of the development of 
MPE was from 18 to 86 years old, and the median 
age was 59.8 years old. Many of these patients had 
IgG or IgA type with plasmacytoma of the lung or 
pleura, or direct invasion of plasma cells into the 
pleura, having StageⅢ according to the Durie and 
Salmom classification. Regarding the distribution 
of gender, and lambda and kappa chain, there 
were no significant differences. Almost half of 
these patients developed left pleural effusion with 
the first development of the MPE. In these 
patients, the survival range was from 10 days to 40 
months, and the average duration was 5.85 months 
after the development of MPE. Almost all patients 
who developed MPE suffered complications of 
pulmonary plasmacytoma or pleural invasion of 
multiple myeloma.
Survival analysis by several factors
　Survival duration was analyzed by several 
factors in patients who developed MPE （Table 2）. 
The distribution of the age and gender, the presence 
or absence of renal dysfunction, and the ratio of 
Fig. １.  CT finding of the chest. Pleural effusion 
developed in the left lung within the wall thickness 
of the pleura.
Fig. ２.  Cytological finding of the pleural effusion. 
Abnormal plasma cells appeared in this sample. 
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plasma cells in the peripheral blood did not significantly 
differ in terms of survival duration. Although the 
patients with renal dysfunction appeared to have 
longer survival duration than those without renal 
dysfunction, there was no significant difference. 
The patients with more than 3.5g/dl serum albumin 
appeared to have shorter survival duration than 
those with a lower level. Furthermore, the patients 
with bone lesion appeared to have shorter survival 
duration than those without bone lesion. However, 
no significant differences were observed. The patients 
at Stage Ⅲ had significantly shorter survival durations 
than the patients at StagesⅠ andⅡ（P＝0.039）. 
Although additionally local treatment with systemic 
chemotherapy appeared to induce longer survival 
duration in MPE patients, there was no significant 
difference.
Characteristics of MPE by lambda
and kappa chain specificity
　The survival duration did not significantly differ 
in terms of the distribution of the lambda and 
kappa chains, age, gender, the ratio of plasma 
cells in the peripheral blood, or the existence of 
bone lesion. Renal dysfunction was more often seen 
in the patients with MPE composed of a lambda 
chain （Table 3；P＝0.017）. Although the patients 
at StagesⅠ andⅡ often had MPE composed of a 
lambda chain, there was no significant difference 
between them.
Discussion
　MPE was a rare complication of multiple myeloma 
patients［2］. Although several kinds of treatments 
were administered, the survival duration of the 
multiple myeloma patients who developed MPE was 
59．8（range from 18 to 86 yo）Age
Gender
26/24M/F
Subtype
30IgG
17IgA
2IgD
1IgM
5LC
2BJP
1null
25/27lambda/kappa
3.56Alb
Stage
4Ⅰ
8Ⅱ
30Ⅲ
Location of effusion
26Left
16Right
11Bilateral
5．85（range from 10 days to 40 months）Survival
Pulmo nary or pleural lesion
42/4＋ /－
PSurvival（months）
Age
0.996.27≧65yo
6.29＜65yo
Gender
0.776.68M
5.88F
Serum albumin
0.233.83≧3.5
8.28＜3.5
Bone lesion
0.304.55Positive
7.13Negative
Plasma cell in peripheral blood
0.985.58Positive
5.66Negative
Renal dysfunction
0.508.11Positive
5.81Negative
Stage
0.0399.77Ⅰ＋Ⅱ
4.18Ⅲ
Local treatment
0.606.71Not added
8.56added
Table １　Characteristics of patients who 
developed MPE
Table２　MPE and several factors related 
 to survival
15函医誌　第32巻　第１号（2008）
indeed miserable［26］. The presented case also died 
of lymphangitis 4 months after the development of 
MPE in spite of treatments with several chemotherapeutic 
agents and local administration of OK432.
　Then we analyzed the previous literature to 
clarify the characteristics of the multiple myeloma 
patients who developed MPE［2-47］. Longer survival 
duration was observed in the patients at StagesⅠ
andⅡ . Many of the patients who developed MPE 
were considered to be experiencing the disease 
progression of multiple myeloma. Although additional 
local treatment to such patients appeared to induce 
longer survival duration, this made no significant 
difference. The average survival duration of the 
patients with only local treatment was shorter than 
that of those with systemic chemotherapy （2.92 
months for patients with only local treatment）. 
This suggests that local treatment was effective for 
the control of MPE but that systemic treatment was 
necessary for further improvement［3, 5, 9, 12, 16-
21, 24, 31, 33, 36, 38, 44］. In our analysis of the 
previous reports, the involvement of β2 microglobulin 
was rarely mentioned. In our analysis, we utilized 
the serum albumin level at the onset of MPE, 
which reflects the disease status according to the 
international score system （ISS）［48］. Although the 
survival duration appeared to be shorter in the 
patients with more than 3.5g/dl serum albumin 
than in those with a lower level, there was no 
significant difference. Therefore, Durie and Salmon 
classification may be more suitable for evaluating 
the prognosis of the patients with MPE than ISS, 
suggesting that MPE develops in a certain and 
unique population of the patients with multiple 
myeloma. However, since ISS includes the data on
β2 microglobulin in addition to those on serum 
albumin, we need to examine through a large-scale 
study whether only serum albumin is sufficient to 
estimate the prognosis without taking β2 microglobulin 
into account.  
　In terms of kappa and lambda chain specificity, 
renal dysfunction was more often seen in the 
patients with MPE composed of a lambda chain. In 
general, renal dysfunction was often observed in 
patients with increased kappa chain［49, 50］. This 
discrepancy might reflect the changes in the 
expression of adhesion molecules, thereby causing 
MPE in the patients with increased lambda chain 
even at the early stage. 
　Based on this analysis, Durie and Salmom 
classification might be suitable for estimating the 
prognosis of patients with MPE. Although the 
prognosis of patients with MPE is actually 
miserable, progress in systemic and local treatment 
can improve the survival duration of patients with 
MPE. Further large-scale study is needed to draw 
a conclusive result. 
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